Adam M Swartz
Overview
Explore the profile of Adam M Swartz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
288
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McCutcheon S, Swartz A, Brown M, Barrera A, McRoberts Amador C, Siklenka K, et al.
Nat Genet
. 2023 Nov;
55(12):2211-2223.
PMID: 37945901
Clinical response to adoptive T cell therapies is associated with the transcriptional and epigenetic state of the cell product. Thus, discovery of regulators of T cell gene networks and their...
2.
McCutcheon S, Swartz A, Brown M, Barrera A, McRoberts Amador C, Siklenka K, et al.
bioRxiv
. 2023 May;
PMID: 37205457
The clinical response to adoptive T cell therapies is strongly associated with transcriptional and epigenetic state. Thus, technologies to discover regulators of T cell gene networks and their corresponding phenotypes...
3.
Parker S, McDowall C, Sanchez-Perez L, Osorio C, Duncker P, Briley A, et al.
Sci Transl Med
. 2023 Feb;
15(682):eabn5649.
PMID: 36753564
D2C7-immunotoxin (IT), a dual-specific IT targeting wild-type epidermal growth factor receptor (EGFR) and mutant EGFR variant III (EGFRvIII) proteins, demonstrates encouraging survival outcomes in a subset of patients with glioblastoma....
4.
Nief C, Swartz A, Chelales E, Sheu L, Crouch B, Ramanujam N, et al.
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230591
Ethanol ablation is a minimally invasive, cost-effective method of destroying tumor tissue through an intratumoral injection of high concentrations of cytotoxic alcohol. Ethyl-cellulose ethanol (ECE) ablation, a modified version of...
5.
Swartz A, Nair S
Curr Protoc
. 2022 Apr;
2(4):e410.
PMID: 35435334
As shown in various preclinical studies, conventional type-1 dendritic cells, or cDC1s, play a critical role in the immunological rejection of tumors and in the defense against pathogens. This indispensability...
6.
Swartz A, Hotchkiss K, Nair S, Sampson J, Batich K
Methods Mol Biol
. 2021 Dec;
2410:609-626.
PMID: 34914072
Our group has employed methodologies for effective ex vivo generation of dendritic cell (DC) vaccines for patients with primary malignant brain tumors. In order to reliably produce the most potent,...
7.
Swartz A, Congdon K, Nair S, Li Q, Herndon 2nd J, Suryadevara C, et al.
NPJ Vaccines
. 2021 Jan;
6(1):12.
PMID: 33462231
Personalized cancer vaccines targeting neoantigens arising from somatic missense mutations are currently being evaluated for the treatment of various cancers due to their potential to elicit a multivalent, tumor-specific immune...
8.
Huang M, Nicholson L, Batich K, Swartz A, Kopin D, Wellford S, et al.
J Clin Invest
. 2019 Oct;
130(2):774-788.
PMID: 31661470
Efficacy of dendritic cell (DC) cancer vaccines is classically thought to depend on their antigen-presenting cell (APC) activity. Studies show, however, that DC vaccine priming of cytotoxic T lymphocytes (CTLs)...
9.
Suryadevara C, Desai R, Farber S, Choi B, Swartz A, Shen S, et al.
Clin Cancer Res
. 2018 Nov;
25(1):358-368.
PMID: 30425092
Purpose: Chimeric antigen receptor (CAR) T cells have shown promise against solid tumors, but their efficacy has been limited, due in part, to immunosuppression by CD4FoxP3 regulatory T cells (Tregs)....
10.
Swartz A, Shen S, Salgado M, Congdon K, Sanchez-Perez L
Expert Opin Biol Ther
. 2018 Oct;
18(11):1159-1170.
PMID: 30281978
Introduction: Conventional therapies for glioblastoma (GBM) typically fail to provide lasting antitumor benefits, owing to their inability to specifically eliminate all malignant cells. Cancer vaccines are currently being evaluated as...